U.S., Sept. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07793929) titled 'A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide' on Aug. 25.
Brief Summary: The primary objective of the study is to estimate the PK parameters of ribupatide in participants with severe renal impairment or end-stage kidney disease (ESKD) after a single dose of ribupatide subcutaneous (SC) injection compared with participants with normal renal function.
Study Start Date: Sept. 08
Study Type: INTERVENTIONAL
Condition:
End Stage Renal Disease
Renal Impairment
Obesity
Overweight
Intervention:
DRUG: Ribupatide
SC Injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Kailera
Disc...